Cobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosque

Vista sencilla de ítem
dc.contributor.authorCarvajal Barrios, Gustavo Adolfo
dc.contributor.authorRamos Rodríguez, Nicolás Ignacio
dc.date.accessioned2024-08-23T20:30:55Z
dc.date.available2024-08-23T20:30:55Z
dc.date.issued2023-04-11
dc.description.abstractDesde la introducción de la vacuna contra la varicela a Colombia no se ha logrado una cobertura mayor al 90%. El objetivo de este trabajo es identificar las barreras de vacunación contra varicela en niños. Metodología. Estudio descriptivo realizado en la Fundación Salud Bosque; se estudiaron 27 pacientes, 18 hombres (67%) y 9 mujeres (33%), incluyendo menores de 18 años con varicela, y excluyendo pacientes con enfermedades ampollosas distintas a varicela y quemaduras. Se hizo una caracterización demográfica. Para las variables cuantitativas se emplearon promedios y desviación estándar, y para las cualitativas la razón de proporción con Stata V12®. Resultados. La incidencia de varicela fue del 0.2%, solo 9 pacientes (33%) habían recibido la primera dosis de la vacuna, ninguno la segunda dosis. El 92.5% requirió incapacidad; el 89% analgésicos; el 63% antihistamínicos y el 26% antibióticos. Discusión. El estudio realizado demuestra una incidencia significativamente menor en contraste con otras cohortes internacionales. En Colombia no se ha alcanzado la cobertura de la vacunación contra la varicela lograda en Uruguay, Costa Rica, Estados Unidos, Australia, Europa y Taiwán, dadas las mismas barreras en su aplicación, mientras que en África no se ha introducido la vacuna contra la varicela porque existen otras prioridades como la desnutrición, la malaria y la infección por Virus de la Inmunodeficiencia Humana. Conclusiones. La cobertura de la vacunación no se ha logrado por barreras modificables que incrementan la incidencia y carga de la enfermedad por costos debido a incapacidad, manejo farmacológico y ausentismo escolar.spa
dc.description.abstractenglishEver since the introduction of the varicella vaccine in Colombia, coverage has not surpassed 90%. The objective of this work is to identify the barriers to varicella vaccination in children. Methodology. A descriptive study conducted at Fundación Salud Bosque. 27 patients were studied - 18 males (67%) and 9 females (33%) - including children under 18 years of age with varicella, and excluding patients with blistering diseases other than varicella and burns. A demographic characterization was conducted. Averages and standard deviations were used for quantitative variables, and the proportion ratio was used for qualitative variables with Stata V12®. Results. The incidence of varicella was 0.2%. Only 9 patients (33%) had received the first dose of the vaccine, and none had received the second dose. 92.5% required sick leave, 89% required painkillers, 63% required antihistamines, and 26% required antibiotics. Discussion. The conducted study shows a significantly lower incidence compared to other international cohorts. Colombia has not achieved the varicella vaccination coverage of Uruguay, Costa Rica, the United States, Australia, Europe and Taiwan due to the barriers to applying it. Meanwhile, the varicella vaccine has not been introduced in Africa because there are other priorities, such as malnutrition, malaria and the Human Immunodeficiency Virus infection. Conclusions. Vaccination coverage has not been achieved because of modifiable barriers that increase the incidence and burden of the disease due to costs of sick leave, pharmacological treatment and school absenteeism.eng
dc.description.abstractotherDesde a introdução da vacina contra varicela na Colômbia, não foi alcançada uma cobertura superior a 90%. O objetivo deste trabalho é identificar as barreiras à vacinação contra varicela em crianças. Metodologia. Estudo descritivo realizado na Fundação Salud Bosque. Foram estudados 27 pacientes, 18 homens (67%) e 9 mulheres (33%), incluindo crianças menores de 18 anos com varicela e excluindo pacientes com outras doenças bolhosas que não varicela e queimaduras. Foi feita uma caracterização demográfica. Média e desvio padrão foram utilizados para as variáveis quantitativas e, para variáveis qualitativas, a razão de proporção com Stata V12®. Resultados. A incidência de varicela foi de 0.2%, apenas 9 pacientes (33%) receberam a primeira dose da vacina, nenhum a segunda dose. 92,5% requeriam atestado; 89% analgésicos; 63% anti-histamínicos e 26% antibióticos. Discussão. O estudo realizado mostra uma incidência significativamente menor em comparação com outras coortes internacionais. A Colômbia não tem atingido a cobertura vacinal contra a varicela alcançada no Uruguai, Costa Rica, Estados Unidos, Austrália, Europa e Taiwan, dadas as mesmas barreiras em sua aplicação, enquanto na África a vacina contra a varicela não foi introduzida. porque existem outras prioridades como a desnutrição, a malária e a infecção pelo Vírus da Imunodeficiência Humana. Conclusões. A cobertura vacinal não foi alcançada dadas as barreiras modificáveis que aumentam a incidência e carga da doença devido aos custos por atestados, manejo farmacológico e absenteísmo escolar.por
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.29375/01237047.4165
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga UNABspa
dc.identifier.issni-ISSN 0123-7047spa
dc.identifier.issne-ISSN 2382-4603spa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.identifier.urihttp://hdl.handle.net/20.500.12749/26187
dc.language.isospaspa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/4165/3800spa
dc.relation.referencesLerman SJ. Why is Chickenpox Called Chickenpox? Clin Pediatr [Internet]. 1981;20(2): 111-112. doi: https:// doi.org/10.1177/000992288102000205
dc.relation.referencesHeininger U, Seward JF. Varicella. Lancet [Internet]. 2006;368(9544):1365–1376. doi: https://doi.org/10.1016/ S0140-6736(06)69561-5
dc.relation.referencesTakahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet [Internet]. 1974;304(7892):1288-1290. doi: https://doi.org/10.1016/ s0140-6736(74)90144-5
dc.relation.referencesPrevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep [Internet]. 1996;45(RR-11):1- 36. Recuperado a partir de: https://www.cdc.gov/mmwr/ preview/mmwrhtml/00042990.html
dc.relation.referencesLópez AS, Guris D, Zimmerman L, Gladden L, Moore T, Haselow DT, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?. Pediatrics [Internet]. 2006;117(6):e1070-e1077. doi: https://doi.org/10.1542/peds.2005-2085
dc.relation.referencesMINSALUD. Introducción de la vacuna contra la varicela y modificación en el esquema nacional de vacunación de Colombia. Circular Externa No. 027 de 2015. [Internet]. Recuperado a partir de: https://www.minsalud.gov.co/ Normatividad_Nuevo/Circular%200027%20de%20 2015.pdf
dc.relation.referencesEspinal CA, Upegui G, Cristancho LM. Indicadores epidemiológicos de varicela en Colombia. Infectio [Internet]. 1998;2(2):77-85. Recuperado a partir de: https://www.revistainfectio.org/index.php/infectio/ article/view/429
dc.relation.referencesBardach A, Cafferata ML, Klein K, Cormick G, Gibbons L, Ruvinsky S. Incidence and Use of Resources for Chickenpox and Herpes Zoster in Latin America and the Caribbean—A Systematic Review and Meta-analysis. Pediatr Infect Dis J [Internet]. 2012;31(12):1263–1268. doi: https://doi.org/10.1097/INF.0b013e31826ff3a5
dc.relation.referencesMINSALUD. Se refuerza la lucha contra la varicela: Niños de 5 años a ponerse la segunda dosis. [Internet]. Recuperado a partir de: https://www.minsalud.gov.co/ Paginas/Se-refuerza-lucha-contra-la-varicela-Niños-de- 5-años-a-ponerse-la-segunda-dosis-.aspx
dc.relation.referencesInstituto Nacional de Salud – INS. Boletín Epidemiológico Semanal. Semana epidemiológica 07, del 9 al 15 de febrero de 2020 [Internet]. Recuperado a partir de: https://www.ins.gov.co/buscadoreventos/ BoletinEpidemiologico/2020_Boletin_ epidemiologico_semana_7.pdf
dc.relation.referencesVarela FH, Araújo-Pinto L, Scotta MC. Global impact of varicella vaccination programs. Hum Vaccin Immunother [Internet]. 2019;15(3):645-657. doi: https://doi.org/10.1080/21645515.2018.1546525
dc.relation.referencesInstituto Nacional de Salud – INS. Protocolo de vigilancia de varicela, versión 03 diciembre 29 de 2020. [Internet]. Recuperado a partir de: https://www.ins.gov. co/buscador-eventos/Lineamientos/Pro_Varicela.pdf
dc.relation.referencesLópez AS, Zhang J, Marin M. Epidemiology of Varicella During the 2-Dose Varicella Vaccination Program - United States, 2005-2014. MMWR Morb Mortal Wkly Rep [Internet]. 2016;2;65(34):902-905. doi: https://doi. org/10.15585/mmwr.mm6534a4
dc.relation.referencesStreng A, Grote V, Rack-Hoch A, Liese JG. Decline of Neurologic Varicella Complications in Children During the First Seven Years After Introduction of Universal Varicella Vaccination in Germany, 2005–2011. Pediatr Infect Dis J [Internet]. 2017;36(1):79–86. doi: https:// doi.org/10.1097/INF.0000000000001356
dc.relation.referencesHelmuth IG, Poulsen A, Suppli CH, Mølbak K. Varicella in Europe - A review of the epidemiology and experience with vaccination. Vaccine [Internet]. 2015;33(21):2406-2413. doi: https://doi.org/10.1016/j. vaccine.2015.03.055
dc.relation.referencesFalleiros-Arlant LH, Pirez-Garcia MC, Avila-Aguero ML, Cashat M, Parellada CI, Wolfson LJ. Burden of varicella in Latin America and the Caribbean: findings from a systematic literature review. BMC Public Health [Internet]. 2019;8:19(2):175-183. doi: https://doi. org/10.1186/s12889-019-6795-0
dc.relation.referencesHussey H, Abdullahi L, Collins J, Muloiwa R, Hussey G, Kagina B. Varicella zoster virus-associated morbidity and mortality in Africa – a systematic review. BMC Infect Dis. [Internet]. 2017;17(1):1-11. doi: https://doi. org/10.1186/s12879-017-2815-9
dc.relation.referencesNanishi E, Hoshina T, Takada H, Ishimura M, Nishio H, Uehara T, et al. A nationwide survey of common viral infections in childhood among patients with primary immunodeficiency diseases. J Infect [Internet]. 2016;73(4):358-368. doi: https://doi.org/10.1016/j. jinf.2016.07.018
dc.relation.referencesHelmuth IG, Poulsen A, Mølbak K. A national registerbased study of paediatric varicella hospitalizations in Denmark 2010–2016. Epidemiol Infect [Internet]. 2017;145(13):2683-2693. doi: https://doi.org/10.1017/ S0950268817001777
dc.relation.referencesMirinaviciute G, Kristensen E, Nakstad B, Flem E. Varicella-Related Primary Health-care Visits, Hospitalizations and Mortality in Norway, 2008-2014. Pediatr Infect Dis J [Internet]. 2017;36(11):1032-1038. doi: https://doi.org/10.1097/inf.0000000000001656
dc.relation.referencesPurssell E, While AE. Does the Use of Antipyretics in Children Who Have Acute Infections Prolong Febrile Illness? A Systematic Review and Meta-Analysis. J Pediatr [Internet]. 2013;163(3):822-827.e1-2. doi: https:// doi.org/10.1016/j.jpeds.2013.03.069
dc.relation.referencesChiappini E, Venturini E, Remaschi G, Principi N, Longhi R, Tovo PA, et al. 2016 Update of the Italian Pediatric Society Guidelines for Management of Fever in Children. J Pediatr [Internet]. 2017;180:1-7.e1. doi: https://doi.org/10.1016/j.jpeds.2016.09.043
dc.relation.referencesPeetoom KK, Smits JJ, Ploum LJ, Verbakel JY, Dinant,1 Jochen GJ, et al. Does well-child care education improve consultations and medication management for childhood fever and common infections? A systematic review. Arch Dis Child [Internet]. 2017;102(3):261-267. doi: https:// doi.org/10.1136/archdischild-2016-311042
dc.relation.referencesTebruegge M, Kuruvilla M, Margarson I. Does the use of calamine or antihistamine provide symptomatic relief from pruritus in children with varicella zoster infection? Arch Dis Child. [Internet]. 2006;91(12):1035-1036. doi: https://doi.org/10.1136/adc.2006.105114
dc.relation.referencesManistarski M, Levin D, Dvir R, Berger-Achituv S, Rosenfeld-Keidar H, Grisaru-Soen G et al. Lessons from an Outbreak of Varicella Infection in Pediatric Hemato- Oncology Patients. Pediatr Infect Dis J [Internet]. 2018;37(7):649-653. doi: https://doi.org/10.1097/ inf.0000000000001920
dc.relation.referencesBrotons M, Campins M, Méndez L, Juste C, Rodrigo JA, Martínez X, et al. Effectiveness of Varicella Vaccines as Postexposure Prophylaxis. Pediatr Infect Dis J [Internet]. 2010;29(1):10–13. doi: https://doi.org/10.1097/ inf.0b013e3181b36022
dc.relation.referencesBapat P, Koren G. The role of VariZIG in pregnancy. Expert Rev. Vaccines [Internet]. 2013;12(11):1243–1248. doi: https://doi.org/10.1586/14760584.2013.844651
dc.relation.referencesMandelbrot L. Fetal varicella – diagnosis, management, and outcome. Prenat Diagn [Internet]. 2012;32(6):511– 518. doi: https://doi.org/10.1002/pd.3843
dc.relation.referencesGallagher KE, Kadokura E, Eckert LO, Miyake S, Mounier-Jack S, Aldea M, et al. Factors influencing completion of multi-dose vaccine schedules in adolescents: a systematic review. BMC Public Health [Internet]. 2016;16:1-17. doi: https://doi.org/10.1186/ s12889-016-2845-z
dc.relation.referencesVezzosi L, Santagati G, Angelillo IF. Knowledge, attitudes, and behaviors of parents towards varicella and its vaccination. BMC Infect Dis. [Internet]. 2017;17(1):1- 8. doi: https://doi.org/10.1186/s12879-017-2247-6
dc.relation.referencesvan Lier A, Tostmann A, Harmsen IA, de Melker HE, Hautvast JA, Ruijs WL. Negative attitude and low intention to vaccinate universally against varicela among public health professionals and parents in the Netherlands: two internet surveys. BMC Infect Dis [Internet]. 2016;16:1-12. doi: https://doi.org/10.1186/ s12879-016-1442-1
dc.relation.referencesLarson HJ, Jarrett C, Eckersberger E, Smith D, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012. Vaccine [Internet]. 2014;32(19):2150–2159. doi: https://doi. org/10.1016/j.vaccine.2014.01.081
dc.relation.referencesInstituto Nacional de Salud – INS. Boletín Epidemiológico Semanal. Semana epidemiológica 02, del 9 al 15 de enero de 2022. [Internet]. Recuperado a partir de: https://www.ins.gov.co/buscadoreventos/ BoletinEpidemiologico/2022_Boletin_ epidemiologico_semana_2.pdf
dc.relation.referencesLee YH, Choe YJ, Cho SI, Kang CR, Bang JH, Oh MD, et al. Effectiveness of Varicella Vaccination Program in Preventing Laboratory-Confirmed Cases in Children in Seoul, Korea. J Korean Med Sci [Internet]. 2016;31(12):1897-1901. doi: https://doi.org/10.3346/ jkms.2016.31.12.1897
dc.relation.referencesSiedler A, Rieck T, Tolksdorf K. Strong Additional Effect of a Second Varicella Vaccine Dose in Children in Germany, 2009-2014. J Pediatr [Internet]. 2016;173:202-206.e2. doi: https://doi.org/10.1016/j. jpeds.2016.02.040
dc.relation.referencesLeung J, Harpaz R. Impact of the Maturing Varicella Vaccination Program on Varicella and Related Outcomes in the United States: 1994–2012. J Pediat Infect Dis Soc [Internet]. 2016;5(4):395-402. doi: https://doi. org/10.1093/jpids/piv044
dc.relation.referencesHobbelen PHF, Stowe J, Amirthalingam G, Miller L, van Hoek AJ, The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Infect [Internet]. 2016;73(3):241-253. doi: https://doi. org/10.1016/j.jinf.2016.05.008
dc.relation.referencesWormsbecker AE, Wang J, Rosella LC, Kwong JC, Seo CY, Crowcroft NS, et al. Twenty Years of Medically- Attended Pediatric Varicella and Herpes Zoster in Ontario, Canada: A Population-Based Study. PLoS ONE [Internet]. 2015;10(7):1-13. doi: https://doi. org/10.1371/journal.pone.0129483
dc.relation.referencesXu Y, Liu Y, Zhang X, Zhang X, Du J, Cai Y, et al. Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019. Hum Vaccin Immunother [Internet]. 2021;17(1):211-216. doi: https://doi.org/10.1080/21645515.2020.1769395
dc.relation.referencesAbdullat M, Hayajneh W, Banni-Issa A, Alshurman A, Marar B, Al-Hajajrah A, et al. Use of health care resources for varicella in the paediatric population, Jordan. East Mediterr Health J [Internet]. 2021;27(2):159-166. doi: https://doi.org/10.26719/2021.27.2.159
dc.relation.referencesChacon-Cruz E, Meroc E, Costa-Clemens SA, Clemens R, Verstraeten T. Economic Evaluation of Universal Varicella Vaccination in Mexico. Pediatr Infect Dis J [Internet]. 2022;41(5):439-444. doi: https://doi. org/10.1097/inf.0000000000003448
dc.relation.referencesAkpo EIH, Cristeau O, Hunjan M, Casabona G. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom. Clin Infect Dis [Internet]. 2021;73(11):e3617-e3626. doi: https://doi.org/10.1093/cid/ciaa1708
dc.relation.referencesMarijam A, Safonova E, Scherbakov M, Shpeer E, Van Oorschot D, Rudakova A, et al. Cost effectiveness and budget impact of universal varicella vaccination in Russia. Hum Vaccin Immunother [Internet]. 2022;18(5):2045152. doi: https://doi.org/10.1080/21645 515.2022.2045152
dc.relation.referencesHeininger U, Pillsbury M, Samant S, Lienert F, Guggisberg P, Gani R, et al. Health Impact and Costeffectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland. Pediatr Infect Dis J [Internet]. 2021;40(6):e217-e221. doi: https:// doi.org/10.1097/inf.0000000000003136
dc.relation.referencesÁvila-Agüero ML, Beltrán S, Brea-del Castillo J, Castillo-Díaz ME, Chaparro LE, Deseda C, et al. Varicella epidemiology in Latin America and the Caribbean. Expert Rev Vaccines [Internet]. 2018;17(2):175-183. doi: https://doi.org/10.1080/14760584.2018.1418327
dc.relation.referencesAlvis-Guzmán N, Paternina-Caicedo A, Alvis-Estrada L, De la Hoz-Restrepo F. Costos directos de varicela complicada en una población pediátrica de Colombia. Rev Salud Pública [Internet]. 2011;13(6):921-929. doi: https://doi.org/10.1590/s0124-00642011000600005
dc.relation.referencesTorres JP, Maza V, Izquierdo G, Contardo V, Conca N, Ducasse K, et al. Caracterización clínica y de costos de la hospitalización asociada a varicela en niños de la Región Metropolitana y de Valparaíso, Chile. Rev Chilena Infectol [Internet]. 2021;38(5):647-654. doi: https://doi. org/10.4067/s0716-10182021000500647
dc.relation.referencesMaglione MA, Das L, Raaen L, Smith A, Chari R, Newberry S, et al. Safety of Vaccines Used for Routine Immunization of U.S. Children: A Systematic Review. Pediatrics [Internet]. 2014;134(2):325–337. doi: https:// doi.org/10.1542/peds.2014-1079
dc.relation.referencesMeyer C, Reiter S. Impfgegner und Impfskeptiker Geschichte, Hintergründe, Thesen, Umgang. Bundesgesundheitsbl-Gesundheitsforsch- Gesundheitsschutz [Internet]. 2004;47(12):1182–1188. doi: https://doi.org/10.1007/s00103-004-0953-x
dc.relation.urihttps://revistas.unab.edu.co/index.php/medunab/issue/view/289spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.localAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.sourceVol. 26 Núm. 1 (2023): abril - julio 2023: Niño, Adolescente, Varicela; 12-20spa
dc.subjectCobertura de Vacunaciónspa
dc.subjectIncidenciaspa
dc.subjectNiñospa
dc.subjectVacuna contra la Varicelaspa
dc.subjectVaricelaspa
dc.subject.keywordsMedical scienceseng
dc.subject.keywordsLife scienceseng
dc.subject.keywordsVaccination Coverageeng
dc.subject.keywordsIncidenceeng
dc.subject.keywordsChildeng
dc.subject.keywordsChickenpox Vaccineeng
dc.subject.keywordsChikenpoxeng
dc.subject.keywordsHealth scienceseng
dc.subject.keywordsCiências médicaspor
dc.subject.keywordsCiências da vidapor
dc.subject.keywordsCiências da saúdepor
dc.subject.keywordsCobertura Vacinalpor
dc.subject.keywordsIncidênciapor
dc.subject.keywordsCriançapor
dc.subject.keywordsVacina contra Varicelapor
dc.subject.keywordsVaricelapor
dc.subject.lembCiencias médicaseng
dc.subject.lembCiencias de la vidaeng
dc.subject.lembCiencias de la saludeng
dc.titleCobertura y barreras de la vacunación contra la varicela en niños que consultaron a la Fundación Salud Bosquespa
dc.title.translatedCoverage of and Barriers to Varicella Vaccination in Children at Fundación Salud Bosqueeng
dc.title.translatedCobertura e barreiras à vacinação contra varicela em crianças que consultaram a Fundação Salud Bosquepor
dc.typeArticleeng
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículospa
dc.type.redcolhttp://purl.org/redcol/resource_type/ART

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Artículo.pdf
Tamaño:
827.65 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
183 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Revista MedUNAB